RQ-43

RQ-43 is a novel quinoline derivative currently under preclinical investigation for the treatment of pancreatic ductal adenocarcinoma (PDAC). Developed by researchers at the University of Kansas Medical Center, the compound functions by inhibiting the epithelial-to-mesenchymal transition (EMT), a process critical for cancer cell migration, invasion, and metastasis. Mechanistically, RQ-43 has been shown to downregulate key EMT-related transcription factors, including Snail and Beta-catenin. In preclinical models, RQ-43 demonstrated dose-dependent cytotoxicity in human and murine PDAC cell lines and significantly reduced tumor weight and metastasis rates in syngeneic orthotopic mouse models.